Safety and efficacy of new anticoagulants in real world clinical practice

Česká verzia

Authors: Olexa P.
Authors place of work: Gerontologická a geriatrická klinika LF UPJŠ a LVN, Košice
Published in the journal: Kardiol Rev Int Med 2019, 21(2): 96-98

Summary

The results of a series of four large randomised clinical studies of dabigatran, rivaroxaban, apixaban and edoxaban vs. warfarin have confirmed a higher efficacy and safety of the innovative treatments compared to warfarin. Their main benefit stems primarily from a dramatic reduction in the incidence of intracranial bleeding, as well as from greater effectiveness in reducing thromboembolism. Real-world data (RWD) represent an additional source of information about the safety and efficacy of each non-vitamin K antagonist oral anticoagulant (NOAC). RWD should be seen as complementary information, adding to the results of randomised studies. With the exception of edoxaban, there is currently sufficient information on the effectiveness and safety of these products from RWD analyses. The objective of this retrospective review analysis is to present the results, unfortunately still little known but important, of the completed RWD safety and efficacy analyses of the NOACs and to highlight their contribution to answering the questions concerning the true efficacy and safety profiles of the individual NOAC molecules in clinical practice.

Keywords:

direct anticoagulants – randomised controlled studies – real word data analyses

Zdroje

1. Kirchhoff P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 38(38): 2893–2962. doi: 10.1093/ eurheartj/ ehw210

2. Conolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139–1151. doi: 10.1056/ NEJMoa0905561.

3. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883–891. doi: 10.1056/ NEJMoa1009638.

4. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981–992. doi: 10.1056/ NEJMoa1107039.

5. Kato ET, Giugliano RP, Ruff CT et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 Trial. J Am Heart Assoc 2016; 5(5): pii: e003432. doi: 10.1161/ JAHA.116.003432.

6. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383(9921): 955–962. doi: 10.1016/
S0140-6736(13)62343-0.

7. Coleman CI, Antz M, Ehlken B et al. Real-world evidence of stroke prevention in patients with non-valvular atrial fibrillation. Int J Cardiol 2016; 203: 882–884. doi: 10.1016/ j.ijcard.2015.09.037.

8. Larsen TB, Skjøth F, Nielsen PB et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016; 353: i3189. doi: 10.1136/ bmj.i3189.

9. Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25(11): 1236–1244. doi: 10.1002/ pds.4034.

10. Tepper PG, Liux X, Mardekian J et al. Ischemic stroke in nonvalvular atrial fibrillation at warfarin initiation: assessment via a large insurance database. Stroke 2017; 48(6): 1487–1494. doi: 10.1161/ STROKEAHA.116.015535.

11. Tepper PG, Mardekian J, Masseria C et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One 2018; 13(11): e0205989. doi: 10.1371/ journal.pone.0205
989.

12. Amin A, Bruno A, Trocio J et al. Real-world medical cost avoidance when new oral anticoagulants are used versus warfarin for venous thromboembolism in the united states. Clin Appl Thromb Hemost 2016; 22(1): 5–11. doi: 10.1177/ 1076029615585
991.

13. Lip GY, Keshishian A, Kamble S et al. Comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 2016; 116(5): 975–986. doi: 10.1160/ TH16-05-0403.

14. Graham DJ, Reichman ME, Wernecke M et al.
Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176(11): 1662–1671. doi: 10.1001/ jamainternmed.2016.5954.

15. Yao X, Abraham NS, Alexander GC et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016; 5(2): pii: e003074. doi: 10.1161/ JAHA.115.003074.

16. Noseworthy PA, Yao X, Abraham NS et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 2016; 150(6): 1302–1312. doi: 10.1016/ j.chest.2016.07.013.

17. Abraham NS, Noseworthy PA, Yao X et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 2017; 152(2): 1014–1022. doi: 10.1053/ j.gastro.2016.12.018

18. Kamble S, Pan X, Phatak H et al. Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on warfarin versus Apixaban 5mg BID, Dabigatran 150 mg BID, or Rivaroxaban 20 mg QD. Circulation 2015; 132 (Suppl 3): A18465.

19. Camm AJ, Amarenco P, Haas S et al. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag 2014; 10: 425–434. doi: 10.2147/ VHRM.S63
298.

20. Coleman CI, Antz M, Ehlken B et al. Real-lifed evidence of stroke prevention in patients with atrial fibrillation. Int J Cardiol 2015; 203: 882–884. doi: 10.1016/ j.ijcard.2015.09.037.

21. Coleman CI, Peacock WF, Bunz TJ et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and prevous stroke or transient ischemic attack. Stroke 2017; 48(8): 2142–2149. doi: 10.1161/ STROKEAHA.117.017474.

22. Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (ETNA-AF-EU). Available at: https:/ / clinicaltrials.gov/ ct2/ show/ NCT02944019.